Table 3 Summary of safety data

TRAEs ≥ grade 3, number of patients (%)

12 (39%)

 Grade 3

10 (32%)

  Immunotherapy-related events

5 (16%)

 Grade 4

2 (6%)

  Immunotherapy-related events

1 (3%)

 Grade 5

0 (0%)

Dose modifications (number of patients)

 • Durvalumab dose interruptions due to TRAEs

 • Cabozantinib dose interruptions or modifications due to TRAEs

 • Discontinuation of cabozantinib or durvalumab due to TRAEs

10 – Durvalumab Treatment delay/hold

14 – Cabozantinib Treatment hold/modifications

3 – Durvalumab Treatment Discontinuation

3 – Cabozantinib Treatment Discontinuation